Temple Health Launches New Fox Chase-Temple Urologic Institute

Dr. Robert Uzzo, CEO and President of Fox Chase Cancer Center
Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute

PHILADELPHIA (April 27, 2023)—Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute, a groundbreaking initiative that will concentrate on both benign and oncologic urology. With over 20 urologists on faculty, the Institute will provide services at multiple locations throughout the greater Philadelphia area.

“Our urologists have experience treating some of the most complex and advanced oncologic and benign urologic conditions. As leaders in the field, our urologists not only stay on top of the latest changes in medicine but often lead the development of new treatment advances and surgical techniques,” said Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase Cancer Center and Executive Director of the Institute. The new Institute’s executive management team includes Alexander Kutikov, MD, FACS, Jack Mydlo, MD, MBA, Daniel Eun, MD, and Jay Simhan, MD, FACS.

Beyond general urologic care, the highly experienced benign urology team specializes in less common procedures such as advanced perineal and abdominal reconstruction, prostate enucleation, bladder augmentation and urinary diversion, complex bladder pathology, and vaginal reconstruction.

The Fox Chase-Temple Urologic Institute will offer patients access to cutting-edge clinical trials, targeted therapies, immunotherapies, and advanced radiation therapies for the treatment of urologic cancers. Its urologic oncologists will collaborate closely with renowned medical and radiation oncologists to take a multidisciplinary approach to treating cancer, including diagnosis, treatment, and follow-up care.

Meeting biweekly to discuss patient cases and potential treatment options, the Institute’s team will leverage their extensive experience as one of the largest fellowship-trained genitourinary cancer teams in the country.

The Fox Chase-Temple Urologic Institute is designed to provide a seamless transition for patients with urologic cancers who require treatment for benign urology conditions following cancer therapy. These services, as well as many others, will be offered at multiple locations, including:

Outpatient Offices:

  • Fox Chase – Buckingham
  • Fox Chase - East Norriton
  • Fox Chase - Huntingdon Pike
  • Temple University Hospital - Main Campus
  • Temple Health - Center City
  • Temple Health-Chestnut Hill Hospital
  • Temple Health - Fort Washington
  • Temple Health - Suburban

Surgical and Inpatient Facilities:

  • Temple University Hospital - Main Campus
  • Fox Chase - Main Campus
  • Temple University Hospital - Jeanes Campus
  • Temple Health-Chestnut Hill Hospital

There are ongoing plans to add providers and expand as the Institute grows.

“With the creation of this new urologic institute, Temple Health and Fox Chase will now be able to extend our exceptional, cutting-edge care to patients closer to their homes,” said Uzzo. “We are thrilled to extend these services to our neighboring communities and are committed to providing our patients with the quality and convenience they deserve from their healthcare providers.”

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427